Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Effetti della Luce Tenue Durante il Parto sul Dolore, l'Ansia e il Progresso del Travaglio (DIM-LIGHT)

26 settembre 2026 aggiornato da: Pınar Erdoğan

Gli Effetti dell'Esposizione alla Luce Tenue (≤80 Lux) Durante il Travaglio sul Dolore, l'Ansia e l'Avanzamento del Parto: Uno Studio Randomizzato Controllato Monocentrico

The environment of the labor room may influence how women experience childbirth. Light levels, in particular, may affect comfort, stress, and the course of labor. However, there is limited high-quality evidence on whether keeping the labor room lighting dim has measurable benefits for mothers.

This study aims to evaluate the effects of dim light exposure during active labor on pain, anxiety, and labor progress. Pregnant women who are in active labor at term will be randomly assigned to one of two groups. One group will give birth in a room with dim lighting (50-80 lux), while the other group will receive standard room lighting as part of routine care.

Pain and anxiety levels will be measured at specific time points during labor using standard assessment scales. Information about labor duration, use of labor medications, mode of delivery, and newborn outcomes will also be collected.

The dim light intervention does not interfere with routine obstetric care and does not pose additional risk to the mother or baby. If needed for clinical reasons, room lighting can be increased immediately. The results of this study may help determine whether a simple change in the birth environment can improve maternal comfort and labor outcomes.

Panoramica dello studio

Descrizione dettagliata

This study is a single-center, parallel-group randomized controlled trial designed to evaluate the effects of dim light exposure during active labor on maternal pain, anxiety, and labor progress. The trial is conducted in a university hospital labor ward and includes term pregnant women in active labor.

Eligible participants are women aged 18-45 years with a singleton, vertex-presenting pregnancy at ≥37 weeks of gestation who are in active labor. Eligible participants are individually randomized in a 1:1 ratio to either the dim-light intervention group or the standard-light control group using a predefined randomization sequence. Randomization is performed at the participant level after confirmation of eligibility and informed consent.

In the intervention group, labor room lighting is adjusted to a dim light environment with an illumination level maintained between 50 and 80 lux, using warm white or amber light sources. Light intensity is monitored at regular intervals using a lux meter. In the control group, routine labor room lighting conditions are maintained in accordance with standard clinical practice.

Pain intensity and anxiety levels are assessed at predefined time points during labor using validated measurement tools. Labor progress and obstetric outcomes, including use of labor augmentation, duration of labor stages, mode of delivery, and neonatal outcomes, are recorded from clinical charts.

The primary outcome is derived from changes in pain intensity over time during labor. Secondary outcomes include anxiety levels, labor characteristics, and maternal and neonatal clinical outcomes.

The dim light intervention is non-invasive and does not interfere with routine obstetric care. For clinical or safety reasons, room lighting can be increased immediately at any time at the discretion of the clinical team. All participants receive standard intrapartum care according to institutional protocols.

Study data are collected prospectively and stored in an anonymized format to ensure participant confidentiality. The study is conducted in accordance with ethical principles and has received approval from the relevant institutional ethics committee.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

120

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Niğde Province
      • Niğde, Niğde Province, Turchia (Türkiye)
        • Niğde Ömer Halisdemir University Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 45 anni (Adulto)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

Pregnant individuals aged 18-45 years

Singleton pregnancy

Vertex (cephalic) presentation

Gestational age ≥37 weeks

Active labor at enrollment (cervical dilation between 4 and 8 cm)

Ability to provide written informed consent

Exclusion Criteria:

Planned or ongoing epidural analgesia

Multiple pregnancy

Severe preeclampsia or other obstetric complications requiring immediate intervention

Known photosensitivity or light-related sensitivity disorders

History of psychiatric disorders that may interfere with anxiety assessment

Any condition deemed by the clinical team to require deviation from the study protocol

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Dim Light (50-80 Lux)

Labor room lighting will be maintained at 50-80 lux using warm white/amber light sources. Illumination will be monitored at regular intervals with a lux meter. Standard intrapartum care will be provided; lighting may be increased immediately if clinically needed.

Adjustment of labor room illumination to a target range of 50-80 lux during active labor, with monitoring using a lux meter; lighting can be increased at any time for clinical reasons.

Comparatore attivo: Routine Lighting (Control)

Routine labor room lighting will be maintained according to standard clinical practice. Standard intrapartum care will be provided.

Standard labor room lighting conditions maintained according to routine clinical practice, without modification of illumination levels.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pain intensity over time (VAS-AUC, 0-120 minutes)
Lasso di tempo: From baseline to 120 minutes during active labor

Pain intensity will be assessed using a 0-10 Visual Analog Scale (VAS) at baseline (0 minutes), 60 minutes, and 120 minutes after allocation. The area under the curve (AUC) for VAS from 0 to 120 minutes will be calculated as the primary outcome.

From baseline to 120 minutes during active labor

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Anxiety level (six-item short-form state anxiety score)
Lasso di tempo: From baseline to 90 minutes during active labor

State anxiety was assessed at baseline (prior to intervention/exposure) and at 90 minutes during active labor using a six-item short form derived from the State scale of the State-Trait Anxiety Inventory (STAI). Each item was rated on a four-point scale, with positively worded items reverse-scored. Item scores were summed to yield a raw total score ranging from 6 to 24, with higher scores indicating greater state anxiety. The between-group difference in anxiety at 90 minutes was evaluated with adjustment for baseline anxiety score.

From baseline to 90 minutes during active labor
Oxytocin use (initiation rate and total dose)
Lasso di tempo: During labor until delivery

Proportion of participants who receive oxytocin augmentation and the total oxytocin dose administered during labor will be recorded from clinical charts.

During labor until delivery
Duration of active phase of labor
Lasso di tempo: From enrollment to full dilation

Time from enrollment during active labor to full cervical dilation will be recorded.

From enrollment to full dilation
Duration of second stage of labor
Lasso di tempo: From full dilation to delivery

Time from full cervical dilation to delivery will be recorded.

From full dilation to delivery
Mode of delivery
Lasso di tempo: At delivery

Vaginal delivery (spontaneous/assisted) and cesarean delivery will be recorded.

At delivery
Estimated blood loss
Lasso di tempo: At delivery / immediate postpartum

Estimated maternal blood loss at delivery will be recorded from clinical records.

At delivery / immediate postpartum
Neonatal outcomes (Apgar scores)
Lasso di tempo: 1 and 5 minutes after birth

Neonatal well-being will be assessed using the Apgar scoring system at 1 and 5 minutes after birth. The Apgar score ranges from 0 to 10, based on five components (heart rate, respiratory effort, muscle tone, reflex irritability, and skin color). Higher Apgar scores indicate better neonatal condition (better outcome). Apgar scores at 1 and 5 minutes will be recorded and analyzed descriptively.

1 and 5 minutes after birth

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

6 gennaio 2026

Completamento primario (Effettivo)

29 maggio 2026

Completamento dello studio (Effettivo)

30 maggio 2026

Date di iscrizione allo studio

Primo inviato

16 dicembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

16 dicembre 2025

Primo Inserito (Effettivo)

30 dicembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

30 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

26 settembre 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data will not be shared due to the sensitive nature of intrapartum clinical data and the absence of participant consent for data sharing beyond the objectives of this study. De-identified aggregate results will be reported through publications.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi